1q12 Promacta sales seem disappointing to me unless there is a big currency issue with the USD sales comparisons. Especially given Nplate performance reported in this thread. AMGN has had advantages n the US from being a biologic, but previously the ROW performance had been more impressive for GSK. I assume no discussion on the conference call?
Market Data 
Markets 
AI
